Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2208 • 2019 ACR/ARP Annual Meeting
Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis
Anahy Brandy-Garcia¹, Melania Martínez-Morillo ¹, Roxana Coras ², Lourdes Mateo-Soria ³, Susana Holgado ¹, Maria Aparicio-Espinar ¹, Águeda Prior-Español ¹, Jordi Camins-Fabregas ⁴, Ivette Casafont-Solé ¹, Annika Nack ¹, Alejandro Olivé-Marqués ⁵, Monica Guma ⁶ and Laia Gifre ¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ². Department of Medicine, School of Medicine. University of California, San Diego, ³Rheumatology Service, Germans Trias i Pujol University Hospital, Spain, ⁴Rheumatology Service, Germans Trias i Pujol University Hospital, Badalona, Spain, ⁵Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ⁶Department of Medicine, School of Medicine. University of California San Diego, La Jolla, United States
Background/Purpose: Patients with elderly-onset arthritis have greater comorbidity than young patients, with a higher incidence of osteoporosis (OP), probably mediated by increased bone resorption. However,…
Abstract Number: 482 • 2019 ACR/ARP Annual Meeting
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Radhika Iyer¹, Amin Zia ¹, Michelle Bloom ¹, Sunil Nagpal ², Navin Rao ², Frédéric Baribaud ³, George Vratsanos ⁴, Wei Wang ⁵, Gary Firestein ⁶, David Boyle ⁵, Jane Buckner ⁷, V. Michael Holers ⁸, Kevin Deane ⁹ and William Robinson ¹⁰, ¹Stanford University, Stanford, ²Janssen R&D, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴JNJ, Raritan, NJ, ⁵University of California, San Diego, San Diego, CA, ⁶University of California, San Diego, San Diego, ⁷Benaroya Research Institute, Seattle, WA, ⁸University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ¹⁰Stanford University, Stanford, CA
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 2269 • 2019 ACR/ARP Annual Meeting
Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year
Nicole Andersen¹, Orit Schieir ², Marie-France Valois ³, Gilles Boire ⁴, Janet Pope ⁵, Glen Hazlewood ⁶, Louis Bessette ⁷, Carol Hitchon ⁸, Diane Tin ⁹, Carter Thorne ¹⁰, Edward Keystone ¹¹, Vivian Bykerk ¹², Susan J. Bartlett ¹ and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹McGill University, Montreal, QC, Canada, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Western University, London, ON, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Laval University, Quebec City, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Southlake Regional Health Centre, Newmarket, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although many RA patients attribute their disease onset to recent life events, results from retrospective studies remain unclear. We compared characteristics of newly diagnosed…
Abstract Number: 485 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis
Candice Low¹, Richard Conway ², Francis Young ¹, Eamonn Molloy ³, Anne Barbara Mongey ³, Gerry Wilson ³, Ursula Fearon ⁴ and Douglas Veale ⁵, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Blackrock Clinic, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁵EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). It is a precursor to…
Abstract Number: 2324 • 2019 ACR/ARP Annual Meeting
Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Francisco Guiñazú¹, Carla Gobbi ², Paula Alba ¹, Carla Maldini ³, Carla Alonso ¹, Alejandro Albiero ¹, Eduardo Albiero ¹, Viviana Neme ⁴, Marcela Demarchi ⁴ and Marcelo Yorio ³, ¹UNIDAD DE REUMATOLOGÍA, CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ²CÁTEDRA DE CLÍNICA MÉDICA I, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ³CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ⁴SERVICIO DE BIOQUÍMICA. HOSPITAL CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina
Background/Purpose: The Metabolic Syndrome (MetS) is an independent factor of cardiovascular morbidity and mortality and most studies show that its prevalence is higher in established…
Abstract Number: 486 • 2019 ACR/ARP Annual Meeting
Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis
Candice Low¹, Richard Conway ², Francis Young ¹, Eamonn Molloy ³, Anne Barbara Mongey ³, Gerry Wilson ³, Ursula Fearon ⁴ and Douglas Veale ⁵, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Blackrock Clinic, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁵EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). In some individuals it is…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Jessica Torres Chichande¹, Santiago Ruta ², Einer Sanchez Prado ³, Alvaro Ruta ¹, Sebastian Magri ¹, Facundo Salvatori ¹ and Rodrigo Garcia Salinas ¹, ¹Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ²Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina, ³Hospital Italiano de La Plata, La Plata
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…
Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Rebecca Overbury¹, Shaobo Pei ², Gopi Penmetsa ³, Brian Sauer ², Vikas Patil ², Jodi Walker ⁴, Jerry Clewell ⁴, Kevin Douglas ⁴, Daniel Clegg ⁵, Grant Cannon ⁶, Ahmad Halwani ⁷ and Jessica Walsh ⁸, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁷Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…
Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Meliha Kapetanovic¹, Maria Andersson ², Alan Friedman ³, Tim Shaw ³, Yanna Song ⁴, Daniel Aletaha ⁵, Maya H. Buch ⁶, Ulf Müller-Ladner ⁷ and Janet Pope ⁸, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ²Abbvie AB, Solna, Sweden, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Medical University of Vienna, Vienna, Austria, ⁶University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁷Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁸Western University, London, ON, Canada
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 623 • 2018 ACR/ARHP Annual Meeting
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
Sofia Pazmino¹, René Westhovens², Veerle Stouten¹, Johan Joly³, Kristien Van der Elst³, Diederik De Cock⁴ and Patrick Verschueren³, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: In the Care in early RA (CareRA) trial, COBRA Slim, a combination of methotrexate (MTX) with a moderate-dose prednisone step-down-bridge scheme, showed a positive…
Abstract Number: 2987 • 2018 ACR/ARHP Annual Meeting
RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
Julie Legrand¹, Thomas Kirchgesner¹, Tatiana Sokolova², Bruno Vande Berg¹ and Patrick Durez², ¹Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Remission is arguably the best and ultimate therapeutic goal in early rheumatoid arthritis (ERA). ERA patients (pts) who reach rapid and sustained remission are…
Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Patrick Durez^2,3, Adrien Nzeusseu Toukap⁴ and Maria Stoenoiu⁵, ¹Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].